Harnessing global legal capabilities and industry knowledge to drive strategic success

hubergroup, headquartered in Germany, is one of the leading international printing inks and chemicals specialists with operations across the world including India, USA, Europe, and Asia.

Within its two divisions, the company develops innovative, sustainable products and services to enable its customers first-class results.

The consortium will acquire all shares in the company from the current owner, Cornelius Treuhand Holding.

Eversheds Sutherland advised on the entire transaction from the bidding process and competition/cartel clearance, to negotiation of all SPAs and all other aspects of the deal.

The global law firm also drew on its repertoire of global legal tech capabilities including DealMaster, an award-winning M&A project management tool.

Led by corporate Partner Steffen Schniepp, the cross-practice Eversheds Sutherland team comprised Partners: Anthony Cross (Corporate), Daniel von Brevern (Antitrust law), Daniel Ehret (Finance), Anette Gärtner (IP), Tobias Maier (IT). Navid Anderson (Counsel), Christian Lindner (Principal Associate), Marian Wieczorke (Counsel), Tim Flaeper (Associate), Rebecca Flachs-Nóbrega (Associate), Doris Perlefein (Associate), Daniel Giese (Associate) (all Corporate).

Steffen Schniepp, Partner, Eversheds Sutherland, said:

“We’ve thoroughly enjoyed advising hubergroup on this highly notable transaction, one of the most complex and prestigious in Germany in the last six months. Our global platform and legal capability truly complemented the nature and complexity of this deal, so it was an absolute pleasure to be able to draw on a combination of that in order to achieve each of our client’s strategic objectives as well as successfully deliver the transaction. I was particularly thrilled to work alongside a highly professional management team, impressively led by Britta Hübner. The collaborative approach taken by all those involved was equally welcome.”

The completion of the transaction is subject to the required regulatory approvals.